Novo Nordisk’s stock received a boost as competitor Eli Lilly raised prices for Zepbound, a drug that competes with Novo Nordisk’s Wegovy. Investors responded positively, pushing Novo Nordisk’s share price up by almost 3%. The move follows a Trump administration initiative to lower drug prices, with Eli Lilly indicating that it will raise prices in the U.K. and other European markets. While Novo Nordisk has not announced similar price hikes, customer backlash could affect both companies. Investors should consider all factors before investing in Novo Nordisk.

Read more at Nasdaq: Why Novo Nordisk Flew Almost 3% Higher on Friday